|
Reference
|
n
|
Males (%)
|
Median age
|
Receiving CT (%)
|
ORR (%)
|
OS (months)
|
PFS (months)
|
|---|
|
Grigoriu et al. 2007 [13]
|
96
|
81
|
65
|
85
|
NR
|
m > 3.5 = 7.0
|
NR
|
|
m ≤ 3.5 = 19.0
|
|
P = 0.003
|
|
Cristaudo et al. 2007 [34]
|
107
|
83.2
|
69
|
NR
|
NR
|
m > 1 = 9.8
|
NR
|
|
m ≤ 1 = 21.5
|
|
P < 0.001
|
|
Creaney et al. 2011 [25]
|
97
|
89
|
66
|
69
| |
m < 1 = 20.3
|
NR
|
|
m > 5 = 12.5
|
|
p = 0.01
|
|
Mori et al. 2013 [35]
|
26
|
21
|
5
|
26
|
19.2
|
m < 0.469* = 26.6
|
NR
|
|
m > 0.469* = 10.3
|
|
p = 0.027
|
|
This study
|
53
|
68
|
69
|
57**
|
m > 2.7 = 26
|
m > 2.7 = 11.3
|
m > 2.7 = 5.1
|
| | | | | |
m ≤ 2.7 = 0
|
m ≤ 2.7 = 17.2
|
m ≤ 2.7 = 8.0
|
| | | | | | | |
P = 0.059†
|
| | | | | | |
P = 0.088
| |
-
n = number patients; ORR, overall response rate; OS, median overall survival; PFS, mean progression free survival; NR, not reported; CT, chemotherapy; m, mesothelin level in nmol/L.
- *This study used the median mesothelin index, calculated by Log2 (mesothelin level after 2 courses of chemotherapy level/mesothelin level prior to chemotherapy). Assay specifically detected N-terminal 31 kDa fragment.
- **18 patients (34%) had a pre-chemotherapy mesothelin level and are therefore included in the response analysis.
-
†If the PFS is analysed as a continuous variable for every unit increase the there is a HR of 1.03, p = 0.013.
